UCB (BE) - UCB and Biogen Idec Discontinue Phase II Clinical Trial of CDP323

Preliminary interim efficacy analysis showed no clinically relevant benefit for patients BRUSSELS (Belgium), 30 June 2009 at 10:30 pm CEST - press release, regulated information - UCB and Biogen Idec announced today the discontinuation of the Phase...

Comments

• Find It

• Recently Written

  • Momenta Loses Generic Copaxon Bid
  • BBC Panorama ? 6 September 2010: ?A Risk Worth Taking?? Programme. GlaxoSmithKline Right of Reply Statement
  • Idenix Provides Update on HCV Clinical Development Activities
  • E-cigarettes gaining steam
  • UK Drug Regulators Want Avandia Pulled From Market
  • A Radical Plan To Save Antibiotics
  • Painkillers: Inappropriate use can push everyday people into addiction
  • Cutting it
  • New Mexico Tenants Notified About Medical Marijuana Policy
  • Paterson police continue searching for gunman who killed city man

• Categories

  • News

• Monthly Archives

  • September 2010
  • August 2010
  • July 2010
  • June 2010
  • May 2010
  • April 2010
  • March 2010
  • February 2010
  • January 2010
  • December 2009
  • November 2009
  • October 2009
  • September 2009
  • August 2009
  • July 2009
  • June 2009
  • May 2009
  • April 2009
  • March 2009
  • February 2009
  • January 2009
  • December 2008
  • November 2008
  • October 2008
  • September 2008
  • August 2008
  • July 2008
  • June 2008
  • May 2008
  • April 2008
  • March 2008
  • February 2008
  • January 2008
  • December 2007
  • November 2007
  • October 2007
  • December 1969

• Blogroll

  • Attorney Daily » Drug Injury News
  • Dangerous Drug Lawyer
  • Drugs.com - Pharma News
  • Health Canada RSS - Media Room
  • Lawyers and Settlements :: Drugs/Medical
  • Medication News
  • MedWatch Safety Alert RSS Feed

• Admin

  • Register
  • Log in
  • XHTML

Copyright © 2010 Drug Injury News